Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini 5, Naples 80131, Italy; Mediterranea Cardiocentro, Via Orazio 2, Naples 80122, Italy.
Department of Advanced Biomedical Sciences, Federico II University of Naples, Via S. Pansini 5, Naples 80131, Italy; Division of Invasive Cardiology, Clinica Montevergine, Via Mario Malzoni, 5, Mercogliano (Avellino) 83013, Italy.
Cardiol Clin. 2020 Nov;38(4):491-505. doi: 10.1016/j.ccl.2020.06.003. Epub 2020 Sep 16.
In patients with multivessel disease, complete revascularization (CR) is the most biologically plausible approach irrespective of definition or type or clinical setting (acute or chronic coronary syndrome [ACS or CCS]). It aims at minimizing residual ischemia, relieving symptoms and reducing the risk of future cardiovascular events. Large evidence supports CR benefits in ACS, predominantly ST-segment elevation myocardial infarction, except cardiogenic shock, although optimal assessment and timing remain debated. In patients with CCS, when revascularization is indicated, a functional CR should be attempted. Therefore, heart-team is crucial in selecting the ideal strategy for each patient to optimize decision-making.
对于多支血管病变患者，无论定义、类型或临床情况（急性或慢性冠状动脉综合征[ACS 或 CCS]）如何，完全血运重建（CR）是最符合生物学原理的方法。它旨在最大限度地减少残留缺血、缓解症状和降低未来心血管事件的风险。大量证据支持 CR 在 ACS 中的获益，主要是 ST 段抬高型心肌梗死，除心源性休克外，尽管最佳评估和时机仍存在争议。对于 CCS 患者，当需要血运重建时，应尝试进行功能 CR。因此，心脏团队在为每位患者选择理想策略以优化决策方面至关重要。
